 WALTHAM, Mass., July 07, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq: APLS, a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to one new employee with a grant date of July 1, 2021, as equity inducement awards outside of the companys 2017 Stock Incentive Plan but under the terms of the 2020 Inducement Stock Incentive Plan and material to the employees acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635c4. 